 | • レポートコード：QYR9NV18004 • 出版社/出版日：QYResearch / 2019年11月18日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、93ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| ※当調査レポートでは、HIV関連リポジストロフィー症候群治療の世界市場について調査・分析し、HIV関連リポジストロフィー症候群治療の世界市場規模、市場動向、主要企業別マーケットシェア、主要地域別市場規模、企業プロフィールなどの情報をまとめました。また、セグメント分析では、種類別（特定薬物治療、美容矯正治療）、用途別（病院、専門医院、その他）、地域別（北米、ヨーロッパ、中国、日本国内、東南アジア、インド、中南米）に区分して市場規模を算出しました。 ・レポートの概要 ・世界のHIV関連リポジストロフィー症候群治療市場動向 ・主要企業別マーケットシェア ・HIV関連リポジストロフィー症候群治療の種類別市場規模2014-2019 （特定薬物治療、美容矯正治療） ・HIV関連リポジストロフィー症候群治療の用途別市場規模2014-2019 （病院、専門医院、その他） ・HIV関連リポジストロフィー症候群治療の北米市場：主要企業・種類別/用途別市場規模 ・HIV関連リポジストロフィー症候群治療のヨーロッパ市場：主要企業・種類別/用途別市場規模 ・HIV関連リポジストロフィー症候群治療の中国市場：主要企業・種類別/用途別市場規模 ・HIV関連リポジストロフィー症候群治療の日本国内市場：主要企業・種類別/用途別市場規模 ・HIV関連リポジストロフィー症候群治療の東南アジア市場：主要企業・種類別/用途別市場規模 ・HIV関連リポジストロフィー症候群治療のインド市場：主要企業・種類別/用途別市場規模 ・HIV関連リポジストロフィー症候群治療の中南米市場：主要企業・種類別/用途別市場規模 ・主要企業のプロフィール （Gilead Sciences、Amgen、Abbott、AstraZeneca、AbbVie、GlaxoSmithKline、Alfa Wassermann SPA、Theratechnologies、Bristol-Myers Squibb） ・HIV関連リポジストロフィー症候群治療の市場規模予測2019-2025 （種類別、用途別、地域別市場予測） ・アナリストの観点・結論 ... |
Lipodystrophy syndrome groups together three clinical conditions characterized by abnormal body fat distribution: lipoatrophy, lipoaccumulation and a mixed syndrome. In 2018, the global HIV Associated Lipodystrophy Syndrome Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global HIV Associated Lipodystrophy Syndrome Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the HIV Associated Lipodystrophy Syndrome Treatment development in North America, Europe and Asia-Pacific.
The key players covered in this study
Gilead Sciences
Amgen
Abbott
AstraZeneca
AbbVie
GlaxoSmithKline
Alfa Wassermann SPA
Theratechnologies
Bristol-Myers Squibb
Market segment by Type, the product can be split into
Specific Drug Treatment
Cosmetic Corrective Treatment
Market segment by Application, split into
Hospital
Specialist Clinic
Others
Market segment by Regions/Countries, this report covers
North America
Europe
Asia-Pacific
The study objectives of this report are:
To analyze global HIV Associated Lipodystrophy Syndrome Treatment status, future forecast, growth opportunity, key market and key players.
To present the HIV Associated Lipodystrophy Syndrome Treatment development in North America, Europe and Asia-Pacific.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of HIV Associated Lipodystrophy Syndrome Treatment are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global HIV Associated Lipodystrophy Syndrome Treatment Market Size Growth Rate by Type (2014-2025)
1.4.2 Specific Drug Treatment
1.4.3 Cosmetic Corrective Treatment
1.5 Market by Application
1.5.1 Global HIV Associated Lipodystrophy Syndrome Treatment Market Share by Application (2019-2025)
1.5.2 Hospital
1.5.3 Specialist Clinic
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 HIV Associated Lipodystrophy Syndrome Treatment Market Size
2.2 HIV Associated Lipodystrophy Syndrome Treatment Growth Trends by Regions
2.2.1 HIV Associated Lipodystrophy Syndrome Treatment Market Size by Regions (2019-2025)
2.2.2 HIV Associated Lipodystrophy Syndrome Treatment Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
3 Market Share by Key Players
3.1 HIV Associated Lipodystrophy Syndrome Treatment Market Size by by Players
3.1.1 Global HIV Associated Lipodystrophy Syndrome Treatment Revenue by by Players (2014-2019)
3.1.2 Global HIV Associated Lipodystrophy Syndrome Treatment Revenue Market Share by by Players (2014-2019)
3.1.3 Global HIV Associated Lipodystrophy Syndrome Treatment Market Concentration Ratio (CR5 and HHI)
3.2 HIV Associated Lipodystrophy Syndrome Treatment Key Players Head office and Area Served
3.3 Key Players HIV Associated Lipodystrophy Syndrome Treatment Product/Solution/Service
3.4 Date of Enter into HIV Associated Lipodystrophy Syndrome Treatment Market
3.5 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type and Application
4.1 Global HIV Associated Lipodystrophy Syndrome Treatment Market Size by Type (2014-2019)
4.2 Global HIV Associated Lipodystrophy Syndrome Treatment Market Size by Application (2014-2019)
5 North America
5.1 North America HIV Associated Lipodystrophy Syndrome Treatment Market Size (2014-2019)
5.2 HIV Associated Lipodystrophy Syndrome Treatment Key Players in North America
5.3 North America HIV Associated Lipodystrophy Syndrome Treatment Market Size by Type
5.4 North America HIV Associated Lipodystrophy Syndrome Treatment Market Size by Application
6 Europe
6.1 Europe HIV Associated Lipodystrophy Syndrome Treatment Market Size (2014-2019)
6.2 HIV Associated Lipodystrophy Syndrome Treatment Key Players in Europe
6.3 Europe HIV Associated Lipodystrophy Syndrome Treatment Market Size by Type
6.4 Europe HIV Associated Lipodystrophy Syndrome Treatment Market Size by Application
7 Asia-Pacific
7.1 Asia-Pacific HIV Associated Lipodystrophy Syndrome Treatment Market Size (2014-2019)
7.2 HIV Associated Lipodystrophy Syndrome Treatment Key Players in Asia-Pacific
7.3 Asia-Pacific HIV Associated Lipodystrophy Syndrome Treatment Market Size by Type
7.4 Asia-Pacific HIV Associated Lipodystrophy Syndrome Treatment Market Size by Application
8 International Players Profiles
8.1 Gilead Sciences
8.1.1 Gilead Sciences Company Details
8.1.2 Company Description and Business Overview
8.1.3 HIV Associated Lipodystrophy Syndrome Treatment Introduction
8.1.4 Gilead Sciences Revenue in HIV Associated Lipodystrophy Syndrome Treatment Business (2014-2019))
8.1.5 Gilead Sciences Recent Development
8.2 Amgen
8.2.1 Amgen Company Details
8.2.2 Company Description and Business Overview
8.2.3 HIV Associated Lipodystrophy Syndrome Treatment Introduction
8.2.4 Amgen Revenue in HIV Associated Lipodystrophy Syndrome Treatment Business (2014-2019)
8.2.5 Amgen Recent Development
8.3 Abbott
8.3.1 Abbott Company Details
8.3.2 Company Description and Business Overview
8.3.3 HIV Associated Lipodystrophy Syndrome Treatment Introduction
8.3.4 Abbott Revenue in HIV Associated Lipodystrophy Syndrome Treatment Business (2014-2019)
8.3.5 Abbott Recent Development
8.4 AstraZeneca
8.4.1 AstraZeneca Company Details
8.4.2 Company Description and Business Overview
8.4.3 HIV Associated Lipodystrophy Syndrome Treatment Introduction
8.4.4 AstraZeneca Revenue in HIV Associated Lipodystrophy Syndrome Treatment Business (2014-2019)
8.4.5 AstraZeneca Recent Development
8.5 AbbVie
8.5.1 AbbVie Company Details
8.5.2 Company Description and Business Overview
8.5.3 HIV Associated Lipodystrophy Syndrome Treatment Introduction
8.5.4 AbbVie Revenue in HIV Associated Lipodystrophy Syndrome Treatment Business (2014-2019)
8.5.5 AbbVie Recent Development
8.6 GlaxoSmithKline
8.6.1 GlaxoSmithKline Company Details
8.6.2 Company Description and Business Overview
8.6.3 HIV Associated Lipodystrophy Syndrome Treatment Introduction
8.6.4 GlaxoSmithKline Revenue in HIV Associated Lipodystrophy Syndrome Treatment Business (2014-2019)
8.6.5 GlaxoSmithKline Recent Development
8.7 Alfa Wassermann SPA
8.7.1 Alfa Wassermann SPA Company Details
8.7.2 Company Description and Business Overview
8.7.3 HIV Associated Lipodystrophy Syndrome Treatment Introduction
8.7.4 Alfa Wassermann SPA Revenue in HIV Associated Lipodystrophy Syndrome Treatment Business (2014-2019)
8.7.5 Alfa Wassermann SPA Recent Development
8.8 Theratechnologies
8.8.1 Theratechnologies Company Details
8.8.2 Company Description and Business Overview
8.8.3 HIV Associated Lipodystrophy Syndrome Treatment Introduction
8.8.4 Theratechnologies Revenue in HIV Associated Lipodystrophy Syndrome Treatment Business (2014-2019)
8.8.5 Theratechnologies Recent Development
8.9 Bristol-Myers Squibb
8.9.1 Bristol-Myers Squibb Company Details
8.9.2 Company Description and Business Overview
8.9.3 HIV Associated Lipodystrophy Syndrome Treatment Introduction
8.9.4 Bristol-Myers Squibb Revenue in HIV Associated Lipodystrophy Syndrome Treatment Business (2014-2019)
8.9.5 Bristol-Myers Squibb Recent Development
9 Market Forecast 2019-2025
9.1 Market Size Forecast by Product (2019-2025)
9.2 Market Size Forecast by Application (2019-2025)
9.3 Market Size Forecast by Regions
9.4 North America
9.5 Europe
9.6 Asia-Pacific
10 Analyst’s Viewpoints/Conclusions
11 Appendix
11.1 Research Methodology
11.1.1 Methodology/Research Approach
11.1.1.1 Research Programs/Design
11.1.1.2 Market Size Estimation
11.1.1.3 Market Breakdown and Data Triangulation
11.1.2 Data Source
11.1.2.1 Secondary Sources
11.1.2.2 Primary Sources
11.2 Disclaimer
11.3 Author Details
Table HIV Associated Lipodystrophy Syndrome Treatment Key Market Segments
Table Key Players HIV Associated Lipodystrophy Syndrome Treatment Covered
Table Global HIV Associated Lipodystrophy Syndrome Treatment Market Size Growth Rate by Type 2018-2025 (Million US$)
Figuer Specific Drug Treatment Figures
Table Key Players of Specific Drug Treatment
Figuer Cosmetic Corrective Treatment Figures
Table Key Players of Cosmetic Corrective Treatment
Table Global HIV Associated Lipodystrophy Syndrome Treatment Market Size Growth by Application 2019-2025 (Million US$)
Figure Global HIV Associated Lipodystrophy Syndrome Treatment Market Share by Application in 2018 & 2025
Figure Hospital Case Studies
Figure Specialist Clinic Case Studies
Figure Others Case Studies
Figure HIV Associated Lipodystrophy Syndrome Treatment Report Years Considered
Figure Global HIV Associated Lipodystrophy Syndrome Treatment Market Size and Growth Rate 2014-2025 (Million US$)
Table Global HIV Associated Lipodystrophy Syndrome Treatment Market Size by Regions 2019-2025 (Million US$)
Table Global HIV Associated Lipodystrophy Syndrome Treatment Market Size by Regions 2019-2025 (Million US$)
Table Global HIV Associated Lipodystrophy Syndrome Treatment Market Share by Regions 2014-2019
Figure Global HIV Associated Lipodystrophy Syndrome Treatment Market Share by Regions 2014-2019
Figure Global HIV Associated Lipodystrophy Syndrome Treatment Market Share by Regions in 2018
Table Market Top Trends
Table Key Drivers: Impact Analysis (2019-2025)
Table Key Challenges
Figure PORTER'S FIVE FORCES ANALYSIS
Table Global HIV Associated Lipodystrophy Syndrome Treatment Revenue by by Players (2014-2019) (Million US$)
Table Global HIV Associated Lipodystrophy Syndrome Treatment Market Share by by Players (2014-2019)
Figure Global HIV Associated Lipodystrophy Syndrome Treatment Market Share by by Players in 2018
Table Global HIV Associated Lipodystrophy Syndrome Treatment by Players Market Concentration Ratio (CR5 and HHI)
Table Key Players Head office and Area Served
Table Key Players HIV Associated Lipodystrophy Syndrome Treatment Product/Solution/Service
Table Date of Enter into HIV Associated Lipodystrophy Syndrome Treatment Market
Table Mergers & Acquisitions, Expansion Plans
Table Global HIV Associated Lipodystrophy Syndrome Treatment Market Size by Type (2014-2019) (Million US$)
Table Global HIV Associated Lipodystrophy Syndrome Treatment Market Size Share by Type (2014-2019)
Figure Global HIV Associated Lipodystrophy Syndrome Treatment Market Size Market Share by Type (2014-2019)
Table Global HIV Associated Lipodystrophy Syndrome Treatment Market Size by Application (2014-2019) (Million US$)
Table Global HIV Associated Lipodystrophy Syndrome Treatment Market Size Share by Application (2014-2019)
Figure Global HIV Associated Lipodystrophy Syndrome Treatment Market Size Market Share by Application (2014-2019)
Figure Global HIV Associated Lipodystrophy Syndrome Treatment Revenue Market Share by Application in 2018
Figure North America HIV Associated Lipodystrophy Syndrome Treatment Market Size 2014-2019 (Million US$)
Table North America Key Players HIV Associated Lipodystrophy Syndrome Treatment Revenue (2018-2019) (Million US$)
Table North America Key Players HIV Associated Lipodystrophy Syndrome Treatment Market Share (2018-2019)
Table North America HIV Associated Lipodystrophy Syndrome Treatment Market Size by Type 2014-2019 (Million US$)
Table North America HIV Associated Lipodystrophy Syndrome Treatment Market Share by Type 2014-2019
Table North America HIV Associated Lipodystrophy Syndrome Treatment Market Size by Application 2014-2019 (Million US$)
Table North America HIV Associated Lipodystrophy Syndrome Treatment Market Share by Application 2014-2019
Figure Europe HIV Associated Lipodystrophy Syndrome Treatment Market Size 2014-2019 (Million US$)
Table Europe Key Players HIV Associated Lipodystrophy Syndrome Treatment Revenue (2018-2019) (Million US$)
Table Europe Key Players HIV Associated Lipodystrophy Syndrome Treatment Market Share (2018-2019)
Table Europe HIV Associated Lipodystrophy Syndrome Treatment Market Size by Type 2014-2019 (Million US$)
Table Europe HIV Associated Lipodystrophy Syndrome Treatment Market Share by Type 2014-2019
Table Europe HIV Associated Lipodystrophy Syndrome Treatment Market Size by Application 2014-2019 (Million US$)
Table Europe HIV Associated Lipodystrophy Syndrome Treatment Market Share by Application 2014-2019
Figure Asia-Pacific HIV Associated Lipodystrophy Syndrome Treatment Market Size 2014-2019 (Million US$)
Table Asia-Pacific Key Players HIV Associated Lipodystrophy Syndrome Treatment Revenue (2018-2019) (Million US$)
Table Asia-Pacific Key Players HIV Associated Lipodystrophy Syndrome Treatment Market Share (2018-2019)
Table Asia-Pacific HIV Associated Lipodystrophy Syndrome Treatment Market Size by Type 2014-2019 (Million US$)
Table Asia-Pacific HIV Associated Lipodystrophy Syndrome Treatment Market Share by Type 2014-2019
Table Asia-Pacific HIV Associated Lipodystrophy Syndrome Treatment Market Size by Application 2014-2019 (Million US$)
Table Asia-Pacific HIV Associated Lipodystrophy Syndrome Treatment Market Share by Application 2014-2019
Table Gilead Sciences Company Details
Table Gilead Sciences Revenue in HIV Associated Lipodystrophy Syndrome Treatment Business 2014-2019 (Million US$)
Figure Gilead Sciences Revenue Growth Rate in HIV Associated Lipodystrophy Syndrome Treatment Business (2014-2019)
Table Gilead Sciences Recent Development
Table Amgen Company Details
Table Amgen Revenue in HIV Associated Lipodystrophy Syndrome Treatment Business 2014-2019 (Million US$)
Figure Amgen Revenue Growth Rate in HIV Associated Lipodystrophy Syndrome Treatment Business (2014-2019)
Table Amgen Recent Development
Table Abbott Company Details
Table Abbott Revenue in HIV Associated Lipodystrophy Syndrome Treatment Business 2014-2019 (Million US$)
Figure Abbott Revenue Growth Rate in HIV Associated Lipodystrophy Syndrome Treatment Business (2014-2019)
Table Abbott Recent Development
Table AstraZeneca Company Details
Table AstraZeneca Revenue in HIV Associated Lipodystrophy Syndrome Treatment Business 2014-2019 (Million US$)
Figure AstraZeneca Revenue Growth Rate in HIV Associated Lipodystrophy Syndrome Treatment Business (2014-2019)
Table AstraZeneca Recent Development
Table AbbVie Company Details
Table AbbVie Revenue in HIV Associated Lipodystrophy Syndrome Treatment Business 2014-2019 (Million US$)
Figure AbbVie Revenue Growth Rate in HIV Associated Lipodystrophy Syndrome Treatment Business (2014-2019)
Table AbbVie Recent Development
Table GlaxoSmithKline Company Details
Table GlaxoSmithKline Revenue in HIV Associated Lipodystrophy Syndrome Treatment Business 2014-2019 (Million US$)
Figure GlaxoSmithKline Revenue Growth Rate in HIV Associated Lipodystrophy Syndrome Treatment Business (2014-2019)
Table GlaxoSmithKline Recent Development
Table Alfa Wassermann SPA Company Details
Table Alfa Wassermann SPA Revenue in HIV Associated Lipodystrophy Syndrome Treatment Business 2014-2019 (Million US$)
Figure Alfa Wassermann SPA Revenue Growth Rate in HIV Associated Lipodystrophy Syndrome Treatment Business (2014-2019)
Table Alfa Wassermann SPA Recent Development
Table Theratechnologies Company Details
Table Theratechnologies Revenue in HIV Associated Lipodystrophy Syndrome Treatment Business 2014-2019 (Million US$)
Figure Theratechnologies Revenue Growth Rate in HIV Associated Lipodystrophy Syndrome Treatment Business (2014-2019)
Table Theratechnologies Recent Development
Table Bristol-Myers Squibb Company Details
Table Bristol-Myers Squibb Revenue in HIV Associated Lipodystrophy Syndrome Treatment Business 2014-2019 (Million US$)
Figure Bristol-Myers Squibb Revenue Growth Rate in HIV Associated Lipodystrophy Syndrome Treatment Business (2014-2019)
Table Bristol-Myers Squibb Recent Development
Table Global HIV Associated Lipodystrophy Syndrome Treatment Market Size by Regions (Million US$) 2019-2025
Figure Global HIV Associated Lipodystrophy Syndrome Treatment Market Size Share by Regions (2019-2025)
Figure Global HIV Associated Lipodystrophy Syndrome Treatment Market Size Share by Regions in 2025
Figure North America HIV Associated Lipodystrophy Syndrome Treatment Market Size Forecast (2019-2025)(Million USD)
Figure Europe HIV Associated Lipodystrophy Syndrome Treatment Market Size Forecast (2019-2025)(Million USD)
Figure Asia-Pacific HIV Associated Lipodystrophy Syndrome Treatment Market Size Forecast (2019-2025)(Million USD)
Table Global HIV Associated Lipodystrophy Syndrome Treatment Market Size by Product (2019-2025) (Million US$)
Figure Global HIV Associated Lipodystrophy Syndrome Treatment Market Size by Product (2019-2025)
Figure Global HIV Associated Lipodystrophy Syndrome Treatment Market Size by Product in 2025
Table Global HIV Associated Lipodystrophy Syndrome Treatment Market Size by Application (2019-2025) (Million US$)
Figure Global HIV Associated Lipodystrophy Syndrome Treatment Market Size by Application (2019-2025)
Figure Global HIV Associated Lipodystrophy Syndrome Treatment Market Size by Application in 2025
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources
HIV関連リポジストロフィー症候群治療のグローバル市場：規模・現状・予測2019-2025 Lipodystrophy syndrome groups together three clinical conditions characterized by abnormal body fat distribution: lipoatrophy, lipoaccumulation and a mixed syndrome. In 2018, the global HIV Associated Lipodystrophy Syndrome Treatment market size was xx million US$ and it is expected to reach xx mill…- HIV関連リポジストロフィー症候群治療のグローバル市場：規模・現状・予測2019-2025 Lipodystrophy syndrome groups together three clinical conditions characterized by abnormal body fat distribution: lipoatrophy, lipoaccumulation and a mixed syndrome. In 2018, the global HIV Associated Lipodystrophy Syndrome Treatment market size was xx million US$ and it is expected to reach xx mill…
- レノックスガストー症候群治療のグローバル市場：規模・現状・予測2019-2025 Lennox–Gastaut syndrome (LGS) is a complex, rare, and severe childhood-onset epilepsy. It is characterized by multiple and concurrent seizure types, cognitive dysfunction, and slow spike waves on electroencephalogram (EEG). Typically, it presents in children aged 3–5 years and can persist into adult…
- レノックスガストー症候群治療のグローバル市場：規模・現状・予測2019-2025 Lennox–Gastaut syndrome (LGS) is a complex, rare, and severe childhood-onset epilepsy. It is characterized by multiple and concurrent seizure types, cognitive dysfunction, and slow spike waves on electroencephalogram (EEG). Typically, it presents in children aged 3–5 years and can persist into adult…
- レノックスガストー症候群治療のグローバル市場：規模・現状・予測2019-2025 Lennox–Gastaut syndrome (LGS) is a complex, rare, and severe childhood-onset epilepsy. It is characterized by multiple and concurrent seizure types, cognitive dysfunction, and slow spike waves on electroencephalogram (EEG). Typically, it presents in children aged 3–5 years and can persist into adult…